Blood Cancer Diagnostics Market Size & Growth Forecast 2027–2036, By Segments (Product, Test, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Blood Cancer Diagnostics Market size was worth USD 12.2 billion in 2026 and is expected to grow at a 6.56% CAGR between 2027 and 2036, reaching USD 23.03 billion by 2036. The industry revenue for 2027 is assessed at USD 12.87 billion.
Get more details on this report
Request Free Sample ReportBlood Cancer Diagnostics Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 39.96% share, supported by advanced diagnostic infrastructure, widespread molecular testing, and high clinical testing volumes across hospitals and cancer centers.
- Asia Pacific is growing at a 7.8% CAGR, driven by expanding laboratory capacity, improved access to cancer testing, and increasing adoption of advanced diagnostic methods.
Segment Momentum
- Assay Kits and Reagents accounted for 69.5% of the market in 2026 due to their essential role in routine testing, supporting standardized sample preparation, reliable detection, and consistent diagnostic workflows across laboratories.
- Molecular Test is the fastest-growing segment because it provides more specific disease characterization by detecting genetic and molecular changes, supporting increasingly precision-focused diagnostic decision-making.
Market Expansion Drivers
- Increasing incidence of leukemia and related malignancies driving demand for advanced diagnostic testing.
- Advancements in NGS and molecular diagnostics improving blood cancer detection speed and precision.
- Expanding investment in personalized medicine and liquid biopsy technologies enhancing diagnostic innovation.
Leading Market Participants
- Major companies in the blood cancer diagnostics market include Danaher Corporation (United States), Abbott Laboratories (United States), Illumina, Inc. (United States), Bio-Rad Laboratories, Inc. (United States), QIAGEN N.V. (Netherlands), Adaptive Biotechnologies Corporation (United States), Quest Diagnostics Incorporated (United States), SOPHiA GENETICS SA (Switzerland), InVivoScribe, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 12.2 billion
- 2027 Estimated Market Size: USD 12.87 billion.
- Projected Market Size: USD 23.03 billion by 2036
- Growth Forecast: 6.56% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Assay Kits and Reagents (Product) | Blood Tests (Test) | Hospitals and Clinics (End Use)
- Emerging Opportunity Segment: Assay Kits and Reagents (Product) | Molecular Test (Test) | Hospitals and Clinics (End Use)
Market Growth Drivers and Industry Trends
Increasing incidence of leukemia and related malignancies driving demand for advanced diagnostic testing
The continued burden of leukemia and other blood-related malignancies is increasing the need for timely and reliable diagnostic evaluation, which will drive the blood cancer diagnostics market as healthcare providers seek more effective methods for identifying and characterizing disease. Accurate diagnosis is essential for distinguishing among different blood cancers and determining appropriate treatment pathways, creating demand for diagnostic approaches that can provide detailed information about abnormal cells and disease characteristics. Greater emphasis on earlier identification and appropriate clinical assessment is also supporting the use of advanced testing throughout the diagnostic process.
Advancements in NGS and molecular diagnostics improving blood cancer detection speed and precision
Technological progress in sequencing and molecular testing is enhancing the ability to identify genetic and molecular characteristics associated with blood cancers, helping propel the blood cancer diagnostics market toward more precise diagnostic workflows. Next-generation sequencing can examine multiple genetic markers within a testing process, while molecular diagnostic methods can identify disease-associated alterations that may not be adequately characterized through conventional approaches. These capabilities support more detailed disease classification and can help clinicians obtain relevant diagnostic information with greater precision during clinical evaluation.
Expanding investment in personalized medicine and liquid biopsy technologies enhancing diagnostic innovation
Increasing investment in personalized healthcare is encouraging the development of diagnostic approaches capable of capturing patient-specific disease characteristics, creating new opportunities for the blood cancer diagnostics market through advances in liquid biopsy and other precision-oriented technologies. Liquid biopsy approaches can analyze disease-related biological material obtained from blood, offering a less invasive avenue for assessing molecular changes associated with malignancies. Continued innovation in these technologies is supporting broader exploration of individualized diagnostic strategies and expanding the range of tools available for monitoring and characterizing blood cancers.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing incidence of leukemia and related malignancies driving demand for advanced diagnostic testing | 2.00% | High | North America, Europe | High | Near Term |
| Advancements in NGS and molecular diagnostics improving blood cancer detection speed and precision | 1.90% | High | North America, Asia Pacific | High | Mid Term |
| Expanding investment in personalized medicine and liquid biopsy technologies enhancing diagnostic innovation | 1.50% | Moderate | Europe, North America | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
The blood cancer diagnostics market in North America represented the largest share of 39.96% in 2026, supported by advanced healthcare infrastructure, established diagnostic capabilities, and strong adoption of molecular and laboratory-based testing technologies. Greater awareness of early cancer detection and increasing emphasis on precise disease classification are encouraging the use of sophisticated diagnostic methods. The region’s strong clinical research environment and access to specialized healthcare services further support demand for advanced blood cancer diagnostic solutions.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is witnessing increasing demand as healthcare infrastructure improves and awareness of cancer screening and early diagnosis expands. Growing investment in diagnostic facilities, broader access to specialized testing, and rising adoption of advanced laboratory technologies are supporting market development. Increasing attention to timely identification and treatment planning for hematological malignancies is also encouraging healthcare providers to strengthen diagnostic capabilities across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Advanced Laboratory IntegrationGermany emphasizes highly standardized laboratory diagnostics supported by molecular testing and pathology expertise. Diagnostic providers collaborate with healthcare institutions to improve testing quality and strengthen clinical decision-making for blood cancer management.
France 🇫🇷
Clinical Diagnostics AlignmentFrance supports blood cancer diagnostics through coordinated clinical pathways and increasing adoption of molecular testing techniques. Laboratories prioritize accurate disease characterization and standardized testing approaches that enhance treatment selection and patient management.
Italy 🇮🇹
Specialized Diagnostic NetworksItaly expands blood cancer diagnostics through specialized laboratory networks and wider availability of advanced testing methods. Healthcare providers focus on improving diagnostic consistency and supporting multidisciplinary care for hematologic malignancies.
Japan 🇯🇵
Molecular Testing ExpansionJapan continues integrating advanced molecular diagnostic technologies into blood cancer care pathways. Healthcare organizations in Japan focus on improving diagnostic accuracy through genomic analysis and efficient laboratory workflows that support individualized treatment strategies.
South Korea 🇰🇷
Precision Oncology SupportSouth Korea strengthens blood cancer diagnostics through expanded use of genomic technologies and digital laboratory capabilities. Diagnostic companies collaborate with hospitals to deliver comprehensive testing solutions that improve disease classification and therapeutic decision-making.
United States 🇺🇸
Precision Diagnostic AdoptionThe U.S. blood cancer diagnostics market prioritizes molecular testing, genomic profiling, and advanced laboratory technologies for earlier disease characterization. Healthcare providers continue adopting precision diagnostics that support personalized treatment planning and ongoing disease monitoring.
Segment Leadership and Growth Trends
Blood Cancer Diagnostics Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Assay Kits and Reagents (Largest & Fastest-Growing Segment)
Assay kits and reagents held the largest share of the blood cancer diagnostics market, accounting for 69.5% share in 2026, while also representing the fastest-growing product segment. These products are fundamental to diagnostic workflows, providing the reagents and testing components required to identify and characterize blood cancers accurately. Their broad applicability across laboratory-based diagnostic procedures, combined with increasing demand for reliable and efficient testing, supports sustained adoption. Growing emphasis on earlier disease identification and improved diagnostic precision is further strengthening demand for advanced assay kits and reagents.
Test Segment Analysis: Blood Tests (Largest Segment) vs Molecular Test (Fastest-Growing Segment)
The blood tests segment dominated the blood cancer diagnostics market with a 39.01% share in 2026, supported by its established role in the initial detection, evaluation, and monitoring of blood-related malignancies. Blood-based testing provides a relatively accessible approach for assessing abnormal cell counts and other disease indicators, making it an important component of routine diagnostic workflows. Its widespread clinical use and suitability for repeated patient monitoring continue to reinforce its leading position.
Molecular tests are expected to be the fastest-growing test segment, driven by increasing demand for more precise characterization of cancer at the genetic and molecular level. These tests can identify specific molecular alterations that support disease classification, treatment selection, and monitoring of therapeutic response. Greater emphasis on personalized cancer care and the need for more targeted diagnostic information are accelerating adoption of molecular testing technologies.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Instruments, Assay Kits and Reagents | Assay Kits and Reagents | Assay Kits and Reagents |
| Test | Blood Tests, Imaging Tests, Biopsy, Molecular Test | Blood Tests | Molecular Test |
| End Use | Hospitals and Clinics, Diagnostic Labs, Research Institutes | Hospitals and Clinics | Hospitals and Clinics |
Competitive Landscape and Market Positioning
Top players in the blood cancer diagnostics market:
1. Danaher Corporation (United States)
2. Abbott Laboratories (United States)
3. Illumina Inc. (United States)
4. Bio-Rad Laboratories Inc. (United States)
5. QIAGEN N.V. (Netherlands)
6. Adaptive Biotechnologies Corporation (United States)
7. Quest Diagnostics Incorporated (United States)
8. SOPHiA GENETICS SA (Switzerland)
9. InVivoScribe Inc. (United States)
The blood cancer diagnostics market is witnessing rapid advancements in molecular testing, biomarker identification, and precision diagnostic platforms aimed at improving early detection accuracy. Investments in next-generation sequencing and AI-assisted diagnostic analysis are enhancing clinical decision-making capabilities. Rising demand for personalized oncology care is further driving innovation across the market landscape.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Danaher Corporation (United States) | |||||||
| Abbott Laboratories (United States) | |||||||
| Illumina Inc. (United States) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| QIAGEN N.V. (Netherlands) | |||||||
| Adaptive Biotechnologies Corporation (United States) | |||||||
| Quest Diagnostics Incorporated (United States) | |||||||
| SOPHiA GENETICS SA (Switzerland) | |||||||
| InVivoScribe Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Predicta Biosciences | May-26 | Predicta Biosciences appointed Dr. Craig L. Tendler, a former senior oncology executive at Janssen, to its Board of Directors. This strategic appointment reinforces the company’s leadership in precision oncology diagnostics and is intended to accelerate the commercialization of its molecular diagnostic platform for hematologic malignancies. |
| Leukaemia Project Foundation | Oct-25 | The Leukaemia Project Foundation partnered with the JoyNews Impact Makers Foundation to launch a project for building Ghana’s first specialized Centre for Hematology and Clinical Genetics. This initiative aims to establish critical national infrastructure for blood cancer diagnostics, clinical genetics services, and specialized patient care. |
| Asuragen | Mar-24 | Asuragen received Class C Certification under the EU In Vitro Diagnostic Regulation (IVDR) for its QuantideX qPCR BCR-ABL IS Kit. The certification validates the kit’s performance in monitoring Chronic Myeloid Leukemia (CML) patients by quantifying BCR-ABL1 transcripts, ensuring compliance with updated European diagnostic standards. |
| Adaptive Biotechnologies | Dec-23 | Adaptive Biotechnologies released new clinical datasets for its clonoSEQ assay at the 65th ASH Annual Meeting. The data highlights the expanded utility of minimal residual disease (MRD) testing in clinical practice and trial environments, providing strong evidence for using standardized MRD monitoring in blood cancer patient care. |
| Abbott | Oct-23 | The FDA approved Abbott’s RealTime IDH1 Assay as a companion diagnostic for use with Servier Pharmaceuticals' Tibsovo (ivosidenib). This approval enables the precise identification of IDH1 gene mutations in patients with relapsed or refractory Myelodysplastic Syndromes (MDS), facilitating targeted therapy selection. |
| Cepheid | May-23 | Cepheid, a Danaher subsidiary, received CE mark approval for its Xpert NPM1 Mutation test, a molecular diagnostic tool for Acute Myeloid Leukemia (AML). By utilizing automated real-time RT-PCR technology to quantify mutant NPM1 mRNA transcripts, the test provides an accurate and standardized solution for AML monitoring in Europe. |
| QIAGEN | Mar-23 | QIAGEN entered a strategic partnership with Servier to develop a companion diagnostic test for the IDH1 inhibitor Tibsovo. The initiative focuses on utilizing the QIAGEN Rotor-Gene Q MDx platform to detect IDH1 mutations in AML patients, aiming to improve therapeutic stratification and treatment efficacy. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Blood Cancer Diagnostics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Cancer Type | Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes |
| Biomarker Type | Genetic Biomarkers, Protein Biomarkers, Cytogenetic Biomarkers, Immunophenotypic Biomarkers |
| Purpose of Testing | Screening and Risk Assessment, Initial Diagnosis, Disease Classification, Treatment Selection and Monitoring, Recurrence and Relapse Monitoring |
Blood Cancer Diagnostics Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Diagnostic Testing Pathway Assessment |
|
| Reimbursement and Market Access Landscape |
|
| Biomarker Adoption and Clinical Practice Trends |
|
Need a different cut of the data?
Request Custom ResearchHow much revenue does the blood cancer diagnostics market generate?
How much is the blood cancer diagnostics industry expected to grow by 2036?
How is the rising incidence of blood cancers influencing diagnostic workflow adoption?
What role are molecular diagnostics and NGS playing in transforming testing demand in this market?
Why do Assay Kits and Reagents lead the blood cancer diagnostics market?
Which test segment is expanding the fastest in the blood cancer diagnostics market?
Why does North America dominate the blood cancer diagnostics market?
What is fueling growth in Asia Pacific blood cancer diagnostics?
What are the prominent companies operating in the blood cancer diagnostics landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization